Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Merck
Dow
Express Scripts
McKesson
Mallinckrodt
Johnson and Johnson

Last Updated: January 26, 2023

CLINICAL TRIALS PROFILE FOR CYTOVENE


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Cytovene

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000134 ↗ Studies of the Ocular Complications of AIDS (SOCA)--Cytomegalovirus Retinitis Retreatment Trial (CRRT) Completed Baylor College of Medicine Phase 3 1992-12-01 To compare the relative merits of three therapeutic regimens in patients with AIDS and CMV retinitis who have been previously treated but whose retinitis either is nonresponsive or has relapsed. These three therapeutic regimens were (1) foscarnet, (2) high-dose ganciclovir, and (3) combination foscarnet and ganciclovir. To compare two treatment strategies in patients with relapsed or nonresponsive CMV retinitis: (1) continuing the same anti-CMV drug or (2) switching to the alternate drug.
NCT00000134 ↗ Studies of the Ocular Complications of AIDS (SOCA)--Cytomegalovirus Retinitis Retreatment Trial (CRRT) Completed Icahn School of Medicine at Mount Sinai Phase 3 1992-12-01 To compare the relative merits of three therapeutic regimens in patients with AIDS and CMV retinitis who have been previously treated but whose retinitis either is nonresponsive or has relapsed. These three therapeutic regimens were (1) foscarnet, (2) high-dose ganciclovir, and (3) combination foscarnet and ganciclovir. To compare two treatment strategies in patients with relapsed or nonresponsive CMV retinitis: (1) continuing the same anti-CMV drug or (2) switching to the alternate drug.
NCT00000134 ↗ Studies of the Ocular Complications of AIDS (SOCA)--Cytomegalovirus Retinitis Retreatment Trial (CRRT) Completed Johns Hopkins University Phase 3 1992-12-01 To compare the relative merits of three therapeutic regimens in patients with AIDS and CMV retinitis who have been previously treated but whose retinitis either is nonresponsive or has relapsed. These three therapeutic regimens were (1) foscarnet, (2) high-dose ganciclovir, and (3) combination foscarnet and ganciclovir. To compare two treatment strategies in patients with relapsed or nonresponsive CMV retinitis: (1) continuing the same anti-CMV drug or (2) switching to the alternate drug.
NCT00000134 ↗ Studies of the Ocular Complications of AIDS (SOCA)--Cytomegalovirus Retinitis Retreatment Trial (CRRT) Completed Memorial Sloan Kettering Cancer Center Phase 3 1992-12-01 To compare the relative merits of three therapeutic regimens in patients with AIDS and CMV retinitis who have been previously treated but whose retinitis either is nonresponsive or has relapsed. These three therapeutic regimens were (1) foscarnet, (2) high-dose ganciclovir, and (3) combination foscarnet and ganciclovir. To compare two treatment strategies in patients with relapsed or nonresponsive CMV retinitis: (1) continuing the same anti-CMV drug or (2) switching to the alternate drug.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Cytovene

Condition Name

Condition Name for Cytovene
Intervention Trials
HIV Infections 5
Cytomegalovirus Retinitis 4
Brain Neoplasm 1
MDS 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Cytovene
Intervention Trials
Retinitis 5
HIV Infections 5
Cytomegalovirus Retinitis 5
Lymphoma 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Cytovene

Trials by Country

Trials by Country for Cytovene
Location Trials
United States 36
Canada 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Cytovene
Location Trials
California 4
Pennsylvania 2
Missouri 2
Michigan 2
Massachusetts 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Cytovene

Clinical Trial Phase

Clinical Trial Phase for Cytovene
Clinical Trial Phase Trials
Phase 3 3
Phase 2/Phase 3 2
Phase 2 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Cytovene
Clinical Trial Phase Trials
Completed 8
Recruiting 1
Terminated 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Cytovene

Sponsor Name

Sponsor Name for Cytovene
Sponsor Trials
Johns Hopkins Bloomberg School of Public Health 4
Icahn School of Medicine at Mount Sinai 3
University of California, San Francisco 3
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Cytovene
Sponsor Trials
Other 49
NIH 8
Industry 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Baxter
Merck
McKinsey
Johnson and Johnson
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.